IMP3: A diagnostic and prognostic biomarker in malignant melanoma

Expert Review of Molecular Diagnostics

Volumn 8, Issue 5, 2008, Pages 557-558

  Xu, Haodong ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INOSINE PHOSPHATE; INOSINE PHOSPHATE 3; MESSENGER RNA; RNA BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG;

CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; DIAGNOSTIC VALUE; DISEASE COURSE; EDITORIAL; GENE OVEREXPRESSION; GERM CELL; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOCYTIC NEVUS; MELANOMA; NEUROSECRETORY CELL; OVERALL SURVIVAL; PROGNOSIS; PROTEIN DOMAIN; SURVIVAL RATE; UROGENITAL TRACT TUMOR;

MELANOMA; NEOPLASM PROTEINS; PROGNOSIS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 51849087721     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.5.557     Document Type: Editorial

References (22)

1. Nielsen J, Christiansen J, Lykke-Andersen J et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol. Cell Biol. 19, 1262-1270 (1999).
2. Liao B, Hu Y, Herrick DJ et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J. Biol. Chem. 280, 18517-18524 (2005).
3. Mueller-Pillasch F, Lacher U, Wallrapp C et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14, 2729-2733 (1997).
4. Simon R, Bourne PA, Yang Q et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum. Pathol. 38, 1178-1183 (2007).
5. Hammer NA, Hansen TO, Byskov AG et al. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction 130, 203-212 (2005).
6. Hanley KZ, Facik MS, Bourne PA et al. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer 114, 49-56 (2008).
7. Pryor JG, Simon RA, Bourne PA et al. Merkel cell carcinoma expresses K homology domain-containing protein overexpressed in cancer (KOC) similar to other high-grade neuroendocrine carcinomas. Hum. Pathol. (In Press).
8. Yantiss RK, Woda BA, Fanger GR et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am. J. Surg. Pathol. 29, 188-195 (2005).
9. Jiang Z. Prognostic biomarkers in renal cell carcinoma. Expert Rev. Mol. Diagn. 7, 293-307 (2007).
10. Jiang Z, Lohse CM, Chu PG et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 112, 2676-2682 (2008).
11. Jiang Z, Chu PG, Woda BA et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 7, 556-564 (2006).
12. Li L, Xu H, Spaulding BO et al. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum. Pathol. 39, 1205-1211 (2008).
13. Sitnikova L, Mendese G, Liu Q et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin. Cancer Res. 14, 1701-1706 (2008).
14. Yantiss RK, Cosar E, Fischer AH. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol. 52, 133-138 (2008).
15. Gu L, Shigemasa K, Ohama K. Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int. J. Oncol. 24, 671-678 (2004).
16. Wang T, Fan L, Watanabe Y et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br. J. Cancer 88, 887-894 (2003).
17. Li C, Rock KL, Woda BA et al. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod. Pathol. 20, 242-247 (2007).
18. Li C, Zota V, Woda BA et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod. Pathol. 20, 1263-1268 (2007).
19. Xu H, Bourne PA, Spaulding BO et al. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum. Pathol. 38, 555-563 (2007).
20. Pryor JG, Bourne PA, Yang Q et al. IMP-3 is a novel progression marker in malignant melanoma. Mod. Pathol. 21, 431-437 (2008).
21. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 17, 117-127 (2007).
22. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19, 3635-3648 (2001).